# J.P. Morgan Milan Investor Forum

Milan | September 28, 2017

Robert Adolph - Director IR




**Safe harbor statement**: This presentation includes certain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Act of 1934, as amended. The Company has based these forward-looking statements on current estimates and assumptions made to the best of our knowledge. Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties, including changes in business, economic competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings and the availability of financing. Given these uncertainties, readers should not put undue reliance on any forward-looking statements. These and other risks and uncertainties are discussed in detail in Fresenius Medical Care AG & Co. KGaA's (FMC AG & Co. KGaA) Annual Report on Form 20-F under the heading "Forward-Looking Statements" and under the headings in that report referred to therein, and in FMC AG & Co. KGaA's other reports filed with the Securities and Exchange Commission (SEC) and the German Exchange Commission (Deutsche Börse).

Forward-looking statements represent estimates and assumptions only as of the date that they were made. The information contained in this presentation is subject to change without notice and the company does not undertake any duty to update the forward-looking statements, and the estimates and assumptions associated with them, except to the extent required by applicable law and regulations.

If not mentioned differently the term net income after minorities refers to the net income attributable to the shareholders of Fresenius Medical Care AG Co. KGaA. The term EMEA refers to the region Europe, Middle East and Africa. Amounts are in Euro if not mentioned otherwise.

Agenda	a
1	At a glance
2	Strategy
3	Q2 2017 financials
4	Outlook







Numbers as of June 2017, treatments: last 12 month

# Our solid revenue profile

Percentage of FY 2016 revenue (€, IFRS)

## **Health care services**

**Dialysis Services** 



Therapies & laboratory services for patients with chronic kidney failure

## **11.3**bn

68% 2.2bn



North America -Businesses supporting dialysis, e.g. vascular services

**14**%

## Products

## **Dialysis Products**




e.g., dialysis machines, dialyzers & bloodline systems

**3.1**bn








Segment revenue FY 2016, according to IFRS in EUR bn, number of patients and clinics as of YE 2016, yoy change



# Organic growth drivers

Patient growth driven by

- age, lifestyle and higher life expectancy
- increasing wealth and access to medical treatments







1 Internal estimates as of Dec. 31, 2016

Agenda	
1	At a glance
2	Strategy
3	Q2 2017 financials
4	Outlook
















# -Market position by major product groups<sup>1</sup>

Dialyzers Dialysis machines Hemodialysis concentrates Bloodlines

Peritoneal dialysis products

#1 FME

#2

## Innovating for the patient

## **R&D 2016**

- Spend 147 Euro million (+14%)
- ▶ 5% of product revenue
- 7,748 patents
- 794 employees, FTE (+22%)

### 6008 - new dialysis machine

- Innovative and userfriendly
- Technologies for lower ramp up time, faster cleaning, safer treatments
- Allow skilled nurses more time with patients




1 as of Dec. 31, 2016

### Dialysis services worldwide: Patients treated<sup>1</sup> **North America EMEA FMC** 189,000 **FMC** 59,800 DaVita Diaverum **US Renal Care** 24,000 KfH 19,500 Latin America **Asia-Pacific** FMC 30,400 **FMC** 29,300 Baxter 10,000 **B.Braun** 5,700 Showai-Kai 5,200 Diaverum 5,100 USD We lead in every major market, ~73bn treating > 300,000 patients worldwide Market 1 based on company statements and FME estimates as of Dec. 31, 2016




# Our portfolio of Care Coordination businesses

Mid-term revenue and growth profile – 2020e




Size of bubble indicates absolute revenue contribution in 2020e. Positioning of bubble illustrative.












# Home Dialysis Segment: Increasing Penetration

- Address the evolving needs and expectations of patients
- ▶ 82% of patients and families fully educated on their treatment options would select a home modality<sup>1</sup>

## Home dialysis advantages

- More engaged patients, taking responsibility for their wellbeing while reducing cost of care supporting our value based strategy
- Flexibility to tailor the therapy around the patient's lifestyle while delivering positive clinical results
- Higher patient satisfaction in home environment

### Trends in home dialysis in the U.S. (number of ESRD cases in thousands) 2004-2014<sup>2</sup>



Data Source: https://www.usrds.org/2016/view/v2 01.aspx (figure 1.19)




1 Devoe et al., American Journal of Kidney Disease, 2016) 2 ESRD and Fresenius Medical Care. FME Home Dialysis represents unique patients with any time on HHD or PD

# Home Dialysis Segment: Opportunity

## Significant growth opportunity in home modalities


## Home dialysis treatment by modality in 2016

(in % of ESRD cases)











Agenda	)
1	At a glance
2	Strategy
3	Q2 2017 financials
4	Outlook



# Q2 2017: Net income impacted by headwinds

	<b>Q2 2017</b> € million	<b>Q2 2016</b> € million	Growth in %	Growth in %cc
Revenue	4,471	4,026	11	9
<b>Revenue</b> <sup>1</sup> (excl. VA agreement)	4,473	4,026	11	9
Operating profit (EBIT)	583	571	2	0
<b>EBIT</b> <sup>1</sup> (excl. VA agreement)	591	571	4	2
Net income <sup>2</sup>	269	264	2	0
<b>Net income</b> <sup>1,2</sup> (excl. VA agreement)	274	264	4	2
Basic EPS [€]	0.88	0.86	2	0

- Underlying revenue growth trend fully intact
- Earnings affected by:
  - Higher personnel expenses
  - Higher bad debt expenses
  - Increased foreign currency transaction losses



# -H1 2017: Results in line with FY guidance

	<b>H1 2017</b> € million	<b>H1 2016</b> € million	Growth in %	Growth in %cc
Revenue	9,019	7,942	14	11
<b>Revenue<sup>1</sup></b> (excl. VA agreement)	8,921	7,942	12	9
Operating profit (EBIT)	1,235	1,068	16	13
<b>EBIT</b> <sup>1</sup> (excl. VA agreement)	1,144	1,068	7	5
Net income <sup>2</sup>	577	477	21	19
<b>Net income</b> <sup>1,2</sup> (excl. VA agreement)	523	477	10	8
Basic EPS [€]	1.88	1.56	21	18

Solid growth in group revenue and net income

▶ H1 in line with guidance for FY 2017



1 Excl. VA agreement (€98m revenue, €91m EBIT, €54m net income) | 2 Net income attr. to shareholders of FME | cc = constant currency

# Q2 2017: Top-line growth across all regions

North America	€ million	
Revenue	3,225	+11%
Organic growth		+5%
Asia-Pacific	€ million	
Revenue	417	+19%
Organic growth		+11%

EMEA	€ million	
Revenue	642	+7%
Organic growth		+4%
Latin America	€ million	
Revenue	183	+18%
Organic growth		+15%

- North America with strong organic revenue growth supported by Care Coordination
- Asia-Pacific growth positvely impacted by acquisitions and business growth in China



1	North America	72%
2	EMEA	15%
3	Asia-Pacific	9%
4	Latin America	4%



# Q2 2017: Health Care Services – strong growth

Revenue	<b>Q2 2017</b> € million	<b>Q2 2016</b> € million	Growth in %	Growth in %cc	Organic growth in %	Same market growth in %
Total Health Care	3,649	3,273	11	9	6	3
North America	3,017	2,712	11	8	6	3
of which Care Coordination	698	528	32	29	19	-
EMEA	310	293	6	5	2	3
Asia-Pacific	191	157	22	19	6	5
of which Care Coordination	39	n.a.	n.a.	n.a.	n.a.	_
Latin America	131	111	18	18	18	1

- North American Care Coordination business continues very strong growth
- High growth in Asia-Pacific supported by Cura acquisition
- Growth in EMEA in line with patient growth
- Latin America driven by strong underlying organic growth





cc = constant currency

# Q2 2017: Dialysis Products show good demand

	<b>Q2 2017</b> € million	<b>Q2 2016</b> € million	Growth in %	Growth in %cc
Total Health Care Products	822	753	9	8
Dialysis Products	801	741	8	7
North America	208	204	2	0
EMEA	311	294	6	6
Asia-Pacific	226	194	17	15
Latin America	52	44	17	10
Non-Dialysis Products	21	12	71	71


- Increased sales of products for peritoneal and disposables for hemo dialysis in North America
- Growth in EMEA, Asia-Pacific and Latin America accelerated sequentially





cc= constant currency

# Q2 2017: regional margin profile



Dialysis business margin of 18.2% reflects


- higher expense for personnel, supplies and rent
- gain from a consent agreement on certain pharmaceuticals, lower costs for pharmaceuticals and lower bad debt expenses
- Care Coordination margin of 1.2% reflects
  - higher bad debt expense, lower profit from vascular services and higher costs for pharmacy services
  - sequential margin improvement

Diagrams: different scales applied

FDICAL CARE



# Q2 2017: regional margin profile




Diagrams: different scales applied

FDICAL CARF



 Care Coordination performance impacted by integration cost and building up of business



Agenda	
1	At a glance
2	Strategy
3	Q2 2017 financials
4	Outlook



	Guidance 2017	<b>2016 base</b> (IFRS/€m)
Revenue growth	8 to 10%	16,570
Net income growth	7 to 9%	1,144
	<b>Vision 2020</b> (2014-2020, avg. % p.a.)	<b>2020</b> ² (IFRS/€bn)
Revenue growth	~ 10	24
Net income growth	high single digit	

### **Assumptions:**

- Numbers at constant currency, 2017 target excl. effect from agreement with United States Departments of Veterans Affairs and Justice
- Net income refers to net income attributable to shareholders of FMC AG & Co. KGaA



# Back-up



# Attachment 1

#### Reconciliation of non-IFRS financial measures to the most comparable IFRS measure

### € million

FY 2015	FY 2016	Q2 2017
101	572	970
18	3	18
610	724	670
7,214	6,833	6,387
7,943	8,132	8,045
516	709	721
7,427	7,423	7,324
FY 2015	FY 2016 <sup>1</sup>	Q2 2017 <sup>1</sup>
2,129	2,398	2,586
648	710	748
47	65	61
2,824	3,173	3,395
2.6	2.3	2.2
	101         18         610         7,214         7,214         7,943         516         7,427         FY 2015         2,129         648         47         2,824	101       572         18       3         610       724         7,214       6,833         7,943       8,132         7,943       8,132         7,943       7,423         7,214       6,833         7,214       6,833         7,943       8,132         7,943       8,132         7,943       8,132         7,943       8,132         7,943       8,132         7,943       8,132         7,943       8,132         7,943       8,132         7,943       8,132         7,943       8,132         7,943       8,132         7,943       8,132         7,943       8,132         7,943       8,132         7,943       8,132         7,943       7,423         7,423       7,423         8,132       7,10         2,129       2,398         648       710         47       65         2,824       3,173



1 EBITDA: including largest acquisitions

# Attachment 2

Reconciliation of non-IFRS financial measures to the most comparable IFRS measure

€ million

Cash Flow	Q2 2016	Q2 2017	H1 2016	H1 2017
Acquisitions, investments and net purchases of intangible assets	(190)	(191)	(273)	(352)
+ Proceeds from divestitures	132	9	132	10
= Acquisitions and investments, net of divestitures	(58)	(182)	(141)	(342)

Capital expenditures, net	Q2 2016	Q2 2017	H1 2016	H1 2017
Purchase of property, plant and equipment	(227)	(206)	(453)	(404)
- Proceeds from sale of property, plant & equipment	4	13	7	16
= Capital expenditure, net	(223)	(193)	(446)	(388)



# Attachment 3

Reconciliation of non IFRS financial measures to the most directly comparable IFRS financial measures Operating performance excluding VA agreement – basis for guidance 2017

€ million	Q2 2016	Q2 2017	H1 2016	H1 2017
Revenue	4,026	4,471	7,942	9,019
VA agreement	-	(2)	-	98
Revenue excluding VA agreement	4,026	4,473	7,942	8,921
Operating income (EBIT)	571	583	1,068	1,235
VA agreement		(8)	-	91
Operating income (EBIT) excluding VA agreement	571	591	1,068	1,144
Net income <sup>1</sup>	264	269	477	577
VA agreement	-	(5)	-	54
Net income <sup>1</sup> excluding VA agreement	264	274	477	523



1 attributable to shareholders of FMC AG & Co. KGaA

# Q2 2017: Net income impacted by headwinds

					Excl. VA ag	reement _	
	<b>Q2 2017</b> € million	Q2 2016 € million	Growth in %	<b>Q2 2017</b> € million	Q2 2016 € million	Growth in %	Growth in %cc
Net revenue	4,471	4,026	11	4,473	4,026	11	9
Operating income (EBIT)	583	571	2	591	571	4	2
EBIT-margin in %	13.0	14.2	(1.2) рр	13.2	14.2	(1.0) pp	(0.9) pp
Net interest expense	95	90	5	95	90	5	3
Income before taxes	488	481	2	496	481	3	1
Income tax expense	150	149	1	153	149	3	1
Tax rate in %	30.8	31.1	(0.3) pp	30.9	31.1	(0.2) pp	(0.2) pp
Non-controlling interest	69	68	2	69	68	2	0
Net income <sup>1</sup>	269	264	2	274	264	4	2

Solid revenue<sup>2</sup> growth of 9% at constant currency

As expected net income<sup>2</sup> development at constant currency of 2% impacted by headwinds



# Q2 2017: Strong cash flow generation

	<b>Q2 2017</b> in € million	Q2 2016 in € million	<b>H1 2017</b> <sup>1</sup> in € million	H1 2016 in € million
Operating cash flow	883	604	1,052	767
in % of revenue	19.7	15.0	11.7	9.7
Capital expenditures, net	(193)	(223)	(388)	(446)
Free cash flow	690	381	664	321
Free cash flow, after acquisitions and investments	508	323	322	180

Days sales outstanding (DSO) at 66 days worldwide.





1 Incl.  $205m \ (193m)$  cash contribution from VA agreement

# Q2 2017: Quality outcomes remain on high level

	North A	America	EM	1EA	Latin A	merica	Asia-P	acific
% of patients <sup>1</sup>	Q2 2017	Q1 2017	Q2 2017	Q1 2017	Q2 2017	Q1 2017	Q2 2017	Q1 2017
$Kt/V \ge 1.2$	98	98	95	95	93	92	96	96
No catheter (>90 days)	84	84	81	81	81	81	88	89
Hemoglobin = 10 - 12 g/dl	73	73	78	79	51	51	58	59
Hemoglobin = 10 - 13 g/dl (International)	80	79	78	78	69	67	66	68
Albumin $\geq$ 3.5 g/dl <sup>2</sup>	78	78	86	87	91	90	87	87
Phosphate <sup>3</sup> $\leq$ 5.5 mg/dl	62	63	75	77	77	74	69	67
Calcium 8.4 – 10.2 mg/dl	84	84	74	74	78	75	74	75
Hospitalization days, per patient	10.1	10.0	7.5	7.9	3.9	3.9	3.9	4.0



1 Outcome data in these regions might be more volatile over time as clinic data will be added | 2 International standard BCR CRM470 | 3 Phosphate reported as mg/dL of phosphorus

# Exchange rates

-		H1 2016	FY 2016	H1 2017
€:\$	Period end	1.110	1.054	1.141
	Average	1.116	1.107	1.083
€:CNY	Period end	7.376	7.320	7.739
	Average	7.297	7.352	7.445
€:RUB	Period end	71.520	64.300	67.545
	Average	78.297	74.145	62.806
€:ARS	Period end	16.554	16.718	18.956
	Average	15.987	16.334	17.028
€:BRL	Period end	3,590	3.431	3.760
	Average	4.130	3.856	3.443



# -Financial targets


2016	<b>2017</b> <sup>1</sup> – <b>2020</b>
3.6%	5-7%
6.8%	6-8%
24.1%	15-20%
8.2%	~10%
2016	<b>2017</b> <sup>1</sup> - <b>2020</b>
15.9%	High single digit
15.4%	High single digit
	3.6% 6.8% 24.1% <b>8.2%</b> 2016 15.9%



1 Excluding impact related to an agreement with the United States Department of Veterans Affairs and Justice | 2 Excluding settlement costs for an agreement in principle for the GranuFlo case. All figures and estimates EUR / IFRS

# Our portfolio of Care Coordination businesses


Mid-term high single-digit EBIT margin average targeted – 2020e



Size of bubble indicates absolute EBIT contribution in 2020e. Positioning of bubble illustrative.



# -NxStage Medical: Facts & Figures





## ▶IPO in 2005

- Patients in 21 countries have been treated with NxStage products
- ▶3,400 employees

– 700 in the U.S.

2,700 outside the U.S., primarily in manufacturing

## 2016 revenue of USD 366 million



Transaction Highlights			
I all'saction n	ignights		
Purchase Price	<ul> <li>USD 30.00 per share in cash for acquisition of 100% of NxStage Medical shares</li> <li>Enterprise value of USD 2.0 billion or around EUR 1.7 billion<sup>1</sup></li> </ul>		
EPS Impact	<ul> <li>Accretive to EPS in year 3 from closing</li> <li>Accretive to ROIC in year 4 from closing</li> </ul>		
Financing	<ul> <li>All cash transaction financed with debt</li> <li>Potentially adding 60-70 bp to net debt / EBITDA after closing</li> </ul>		
Closing & Timing	<ul> <li>Transaction closing expected in 2018</li> <li>Customary conditions as required by U.S. and German authorities</li> </ul>		



© | September 2017 40

Transaction Highlights				
Synergy Potential	Initial net cost synergies potential of approximately USD 80 to 100 million p.a. before tax over 3 to 5 years is expected			
Key Synergy Drivers	<ul> <li>Labor efficiencies</li> <li>SG&amp;A</li> <li>Manufacturing</li> <li>Distribution</li> <li>Facility cost avoidance</li> <li>CAPEX</li> </ul>			
Integration Costs	Integration costs of around USD 150 million in the first 3 years from announcement are assumed			



-Financial calendar <sup>1</sup>				
November 2, 2017	Report on 3rd quarter 2017			
November 7, 2017	Credit Suisse Healthcare Conference, Scottsdale			
November 14, 2017	Bryan Garnier Healthcare Conference, Paris			
November 20-23, 2017	BAML Corporate Days Asia			
November 30, 2017	dbAccess Pharmaceutical & Healthcare Corporate Day, London			



 $\ensuremath{1}$  Please note that dates and/or participation might be subject to change

**Constant currency:** Changes in revenue, operating income, net income attributable to shareholders of FMC AG & Co. KGaA and other items include the impact of changes in foreign currency exchange rates. We use the non-IFRS financial measure "at constant exchange rates" or constant currency in our filings to show changes in our revenue, operating income, net income attributable to shareholders of FMC AG & Co. KGaA and other items without giving effect to period-to-period currency fluctuations. Under IFRS, amounts received in local (non-Euro) currency are translated into Euros at the average exchange rate for the period presented. Once we translate the local currency for the constant currency, we then calculate the change, as a percentage, of the current period using the prior period exchange rates versus the prior period. This resulting percentage is a non-IFRS measure referring to a change as a percentage "at constant currency."

We believe that the non-IFRS financial measure constant currency is useful to investors, lenders, and other creditors because such information enables them to gauge the impact of currency fluctuations on a company's revenue, operating income and other items from period to period. However, we also believe that the usefulness of data on constant currency period-over-period changes is subject to limitations, particularly if the currency effects that are eliminated constitute a significant element of our revenue, operating income, net income attributable to shareholders of FMC AG & Co. KGaA and other items and significantly impact our performance. We therefore limit our use of constant currency period-over-period changes to a measure for the impact of currency fluctuations on the translation of local currency into Euros. We do not evaluate our results and performance without considering both constant currency period-over-period changes in non-IFRS revenue, operating income, net income attributable to shareholders of FMC AG & Co. KGaA and other items and changes in revenue, operating income, net income attributable to shareholders of FMC AG & Co. KGaA and other items prepared in accordance with IFRS. We caution the readers of this report to follow a similar approach by considering data on constant currency period-over-period changes only in addition to, and not as a substitute for or superior to, changes in revenue, operating income, net income attributable to shareholders of FMC AG & Co. KGaA and other items prepared in accordance with IFRS. We present the growth rate derived from IFRS measures next to the growth rate derived from non-IFRS measures such as revenue, operating income, net income attributable to shareholders of FMC AG & Co. KGaA and other items. Because the reconciliation is inherent in the disclosure, we believe that a separate reconciliation would not provide

## Contacts

FME Investor Relations Else-Kröner-Str. 1 61352 Bad Homburg v.d.H. Germany Ticker: WKN: ISIN:

FME or FMS (NYSE) 578 580 DE00057858002

### Dr. Dominik Heger

Head of Investor Relations and Corporate Communications Tel: +49-(0) 6172-609-2601 Email: <u>dominik.heger@fmc-ag.com</u>

### Robert Adolph

Director Investor Relations Tel.: +49-(0) 6172-609-2477 Email: robert.adolph@fmc-ag.com

### Philipp Gebhardt

Senior Manager Investor Relations Tel.: +49-(0) 6172-609-7323 Email: philipp.gebhardt@fmc-ag.com



